Related Experiment Video
Updated: Jun 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course
Shuji Murakami1, Tomoyuki Yokose, Haruhiro Saito
1Department of Thoracic Oncology, Kanagawa Cancer Center Hospital, Nakao 1-1-2, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan. murakamis@kcch.jp
Abstract:
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer. The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS. However, the clinical findings have not been well described. Here, we report a case of EML4-ALK-positive lung adenocarcinoma that showed multiple metachronous lesions on the pleura and pulmonary field, suspected to be a recurrence of lung adenocarcinoma after a 20-year disease-free interval. The slow clinical course may be characteristic of EML4-ALK-positive lung adenocarcinoma. Therefore, long-term observation of patients with EML4-ALK-positive lung adenocarcinomas is required after surgery.
Related Concept Videos
Non-LTR Retrotransposons
Atypical Pneumonia
lncRNA - Long Non-coding RNAs